Key highlights
- QUILT-2.005 trial of 370 subjects met the primary efficacy endpoint for BCG-naïve NMIBC
- Statistically significant improvement in efficacy observed compared to BCG alone in CIS patients
- Median duration of response for the ANKTIVA plus BCG cohort has not yet been reached
- Safety data showed adverse events consistent with BCG alone with no treatment-related deaths
- Supplemental Biologics License Application (sBLA) on track for FDA submission by year-end 2026
Clinical Trial Outcomes
ImmunityBio announced that its randomized, controlled QUILT-2.005 trial evaluating intravesical ANKTIVA in combination with Bacillus Calmette-Guerin (BCG) reached its primary efficacy endpoint. The study, involving 370 subjects with high-grade BCG-naïve non-muscle invasive bladder cancer (NMIBC), demonstrated a statistically significant improvement in efficacy for the ANKTIVA plus BCG cohort compared to patients receiving BCG alone. This analysis specifically targeted those with carcinoma in situ, with or without papillary tumors. Management confirmed that the median duration of response has not yet been reached for the combination group, and patient-reported quality of life was maintained throughout the evaluation period.
Treatment Paradigm Shift
The trial results represent a potential shift in the standard of care for NMIBC, a condition where BCG has remained the primary treatment for nearly four decades with minimal innovation. By meeting the primary endpoint, ImmunityBio positions ANKTIVA as a chemotherapy-free immunotherapy option that can be administered directly into the bladder. The safety profile observed in the study was consistent with BCG alone, with no treatment-related deaths reported. The company intends to leverage this data to submit a supplemental Biologics License Application (sBLA) to the FDA by the end of 2026, aiming to move the treatment earlier into the disease course for newly diagnosed patients.
Strategic and Financial Context
- First commercial patients in Europe were treated with ANKTIVA plus BCG in Germany and Austria in early November 2026
- The FDA recently expanded ANKTIVA's label in October 2026 to include BCG-unresponsive NMIBC with papillary-only tumors
- ImmunityBio reported record net product revenue of $50.7 million for the second quarter of 2026
- Marketing authorization was recently secured in the United Arab Emirates for NMIBC and metastatic non-small cell lung cancer
- Company presentation is scheduled for the Jefferies Global Healthcare Conference between November 16 and 19, 2026
Down 30.7% since our story on 9 Nov: $8.63 when we broke it → $5.98 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $8.42 |
|---|---|
| 20 Oct | $8.77 |
| 21 Oct | $8.64 |
| 22 Oct | $8.31 |
| 23 Oct | $8.22 |
| 26 Oct | $7.81 |
| 27 Oct | $8.63 |
| 28 Oct | $8.81 |
| 29 Oct | $8.74 |
| 30 Oct | $8.29 |
| 2 Nov | $7.95 |
| 3 Nov | $8.29 |
| 4 Nov | $8.93 |
| 5 Nov | $8.01 |
| 6 Nov | $8.63 |
| 9 Nov | $7.11 |
| 10 Nov | $6.75 |
| 11 Nov | $6.67 |
| 12 Nov | $6.07 |
| 13 Nov | $6.02 |
| 16 Nov | $5.98 |
Expert Commentary on QUILT-2.005
“For patients with carcinoma in situ with or without papillary tumors, the meaningful improvement in response rates when intravesical ANKTIVA is administered with BCG represents an important practice-changing advance. By improving responses earlier in the disease course, this combination has the potential to help more patients remain disease-free longer, avoid additional treatments.”
| Date | Announcement | Amount |
|---|---|---|
| 04 Nov 2026 | First commercial patients in Europe treated with ANKTIVA plus BCG in Germany and AustriaSource: ir.immunitybio.com | – |
| 14 Oct 2026 | FDA approved expanded label of ANKTIVA plus BCG to include BCG-unresponsive NMIBC with papillary-only tumorsSource: ir.immunitybio.com | – |
| 04 Aug 2026 | Reported Q2 2026 financial results with record net product revenue of $50.7 millionSource: ir.immunitybio.com | $50.7 Million |
| 29 Jul 2026 | Received United Arab Emirates marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLCSource: SEC filing | – |
Management commentary
“These results build on the clinical findings observed in patients with BCG-unresponsive NMIBC and underscore the potential of ANKTIVA plus BCG to become the first chemotherapy-free immunotherapy combination to improve treatment outcomes for patients with BCG-naïve bladder cancer.”
| Share price | $8.63 |
|---|---|
| Market cap | $9.2B |
| Revenue (annual) | $113M |
| 1-month price change | -11.44% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by ImmunityBio, Inc. announcing positive results from the QUILT-2.005 trial for ANKTIVA in bladder cancer.
Track ImmunityBio, Inc. live
Get the next ImmunityBio, Inc. SEC filing seconds after it lands.